Trevena (TRVN) Trading 0% Higher
Trevena Inc (NASDAQ:TRVN) shares traded up 0% during mid-day trading on Monday . The company traded as high as $1.64 and last traded at $1.63. 1,798,000 shares traded hands during mid-day trading, an increase of 83% from the average session volume of 983,988 shares. The stock had previously closed at $1.63.
A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Oppenheimer reiterated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research note on Monday, November 13th. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research note on Wednesday, November 8th. Finally, Needham & Company LLC decreased their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.35.
The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92. The firm has a market capitalization of $105.91, a price-to-earnings ratio of -1.03 and a beta of -0.51.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/trevena-trvn-trading-0-higher.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.